Cory Freedland, PhD


Cory has over 10 years of operational and strategic advisory experience in the life sciences sector. He joined Sofinnova in 2014, and concentrates on biopharmaceutical investments. Cory has been involved in the firm’s investments in NuCana Biomed, Principia Biopharma, Spark Therapeutics, and ZS Pharma (ZSPH).

Cory holds a BA in Psychology and Religious Studies from Connecticut College, PhD in Pharmacology from Wake Forest University School of Medicine, and MBA from the Kellogg School of Management. Before transitioning to life sciences finance, Cory worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. Cory moved to investment banking after Kellogg. Before his transition to healthcare venture, he was a Vice President in the healthcare investment banking practice at Morgan Stanley where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/ diagnostics sectors. Prior to joining Sofinnova, Cory was a Principal at Novo A/S.

(650) 681-8434